Molecular Partners
MOLN
6 hedge funds and large institutions have $14.2M invested in Molecular Partners in 2025 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 0 increasing their positions, 1 reducing their positions, and closing their positions.
20% more funds holding
Funds holding: 5 → 6 (+1)
0.01% less ownership
Funds ownership: 8.88% → 8.87% (-0.01%)
17% less capital invested
Capital invested by funds: $17M → $14.2M (-$2.88M)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of America
Charlotte,
North Carolina
|
+$759 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$2.52K |
MOLN Hedge Fund Activity: Q1 2025 in Review
6 of the 7,469 institutional investors tracked by Wall St. Rank reported a position in Molecular Partners (MOLN) for Q1 2025, worth a combined $14.2M — down 17% from $17M a quarter earlier.
Buyers outnumbered sellers: 1 fund opened new MOLN positions and 0 closed out — a net gain of 1 holder — while 0 added to existing stakes and 1 trimmed.
The largest buyer was Bank of America, opening a new position worth an estimated $759. The largest seller was UBS Group, cutting an estimated $2.52K.
- 6 institutional investors held Molecular Partners (MOLN) as of Q1 2025, up from 5 in Q4 2024.
- Funds reported $14.2M of Molecular Partners stock for Q1 2025, down 17% quarter-over-quarter.
- 1 fund opened new Molecular Partners positions in Q1 2025 and 0 closed out, a net change of +1 holder.
- The largest Molecular Partners buyer in Q1 2025 was Bank of America, an estimated $759 added.
- The largest Molecular Partners seller in Q1 2025 was UBS Group, an estimated $2.52K sold.
Based on aggregated 13F filings for Q1 2025.